Nadia Haj Mohammad1,2, Sophia De Rooij3,4, Maarten Hulshof5, Jelle Ruurda6, Bas Wijnhoven7, Frans Erdkamp8, Meindert Sosef9, Suzanne Gisbertz10, Mark van Berge Henegouwen10, Mirjam Sprangers11, Hanneke van Laarhoven12. 1. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands. n.hajmohammad@amc.nl. 2. Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. n.hajmohammad@amc.nl. 3. Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center Groningen, Groningen, The Netherlands. 4. Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, Amsterdam, The Netherlands. 5. Department of Radiation Oncology, Academic Medical Center, Amsterdam, The Netherlands. 6. Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands. 7. Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 8. Department of Internal Medicine, Zuyderland Medisch Centrum, Heerlen/Sittard/Geleen, The Netherlands. 9. Department of Surgery, Zuyderland Medisch Centrum, Heerlen/Sittard/Geleen, The Netherlands. 10. Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands. 11. Department of Medical Psychology, Academic Medical Center, Amsterdam, The Netherlands. 12. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND AND OBJECTIVES: Neoadjuvant chemoradiation (nCRT) followed by esophagectomy is a treatment with curative intent for resectable esophageal cancer. The aim of this study was to measure activities of daily living (ADL) and quality of life (QoL), and to examine correlates of changes in ADL and QoL. METHODS: A prospective study was performed with three time points (baseline, 1 week after the end of nCRT, 3-months post-surgery) together with a cross-sectional post-treatment study. ADL was measured with the Amsterdam Linear Disability Score (ALDS), and QoL with the EORTC QLQ-C30 and the OES-18. Regression analysis was performed to identify factors associated with changes in ADL and QoL. RESULTS: Seventy-six patients were included in the prospective study, 79 in the cross-sectional study. After nCRT, ALDS decreased from 90 to 88 (P < 0.01) and remained stable after surgery. Global QoL decreased from 75 to 61 (P < 0.01); no significant changes were observed after surgery. Only timing of the measurement of ALDS was negatively associated with non-maximum ALDS (n = 155, based on both studies) and QoL (n = 76) (P < 0.01). CONCLUSIONS: Patients who undergo nCRT plus surgery should be prepared to experience a short-term decline in ADL and QoL. The findings of this study can support patients and healthcare workers to guide expectations. J. Surg. Oncol. 2016;114:684-690.
BACKGROUND AND OBJECTIVES: Neoadjuvant chemoradiation (nCRT) followed by esophagectomy is a treatment with curative intent for resectable esophageal cancer. The aim of this study was to measure activities of daily living (ADL) and quality of life (QoL), and to examine correlates of changes in ADL and QoL. METHODS: A prospective study was performed with three time points (baseline, 1 week after the end of nCRT, 3-months post-surgery) together with a cross-sectional post-treatment study. ADL was measured with the Amsterdam Linear Disability Score (ALDS), and QoL with the EORTC QLQ-C30 and the OES-18. Regression analysis was performed to identify factors associated with changes in ADL and QoL. RESULTS: Seventy-six patients were included in the prospective study, 79 in the cross-sectional study. After nCRT, ALDS decreased from 90 to 88 (P < 0.01) and remained stable after surgery. Global QoL decreased from 75 to 61 (P < 0.01); no significant changes were observed after surgery. Only timing of the measurement of ALDS was negatively associated with non-maximum ALDS (n = 155, based on both studies) and QoL (n = 76) (P < 0.01). CONCLUSIONS:Patients who undergo nCRT plus surgery should be prepared to experience a short-term decline in ADL and QoL. The findings of this study can support patients and healthcare workers to guide expectations. J. Surg. Oncol. 2016;114:684-690.
Authors: Jaidyn Muhandiramge; Suzanne G Orchard; Erica T Warner; Gijsberta J van Londen; John R Zalcberg Journal: Cancers (Basel) Date: 2022-03-08 Impact factor: 6.639